Novel and Emerging Agents in NSCLC

This chapter will review the latest emerging novel targeted agents and gene therapy in nonsmall cell lung cancer treatment. In the targeted therapies section, each class of drug will have a review of the scientific rationale and an update on the clinical development. Among the agents reviewed are hsp90 inhibitors, MET/HCF inhibitors, MEK inhibitors for KRAS mutated patients, PI3K/AKT/mTOR inhibitors, PARP inhibitors, NOTCH/Hedgehog pathway inhibitors, and mitotic inhibitors. The gene therapy section will focus on the science and background behind p53 gene replacement, review the clinical trial studies completed to date, and discuss the clinical trial results of FUS1 replacement with DOTAP.